Back to today’s briefing

Story perspectives

New Treatment Boosts Stomach Cancer Survival by 67.4%

6/2/2025

50 6

Summary

Story summary

In a groundbreaking study at Memorial Sloan Kettering Cancer Center, the Matterhorn Phase 3 clinical trial revealed that combining the immunotherapy durvalumab with standard chemotherapy dramatically lowers the chances of stomach and esophageal cancer returning. Patients receiving this innovative treatment enjoyed a remarkable 67.4% event-free survival rate at two years, surpassing the 58.5% rate for those on chemotherapy alone.

1 of 1

Story summary

In a groundbreaking study at Memorial Sloan Kettering Cancer Center, the Matterhorn Phase 3 clinical trial revealed that combining the immunotherapy durvalumab with standard chemotherapy dramatically lowers the chances of stomach and esophageal cancer returning. Patients receiving this innovative treatment enjoyed a remarkable 67.4% event-free survival rate at two years, surpassing the 58.5% rate for those on chemotherapy alone.